Navigate
X
    QualityStocks
  • 18 years ago

XenoPort, Inc. (NASDAQ: XNPT)

XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company, focuses their efforts on developing a portfolio of internally discovered product candidates that leverage the body’s natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The company has directed their focus on developing and commercializing on potential treatments of central nervous system, or CNS, disorders. Their most advanced product candidate, XP13512 (also known as Solzira™), is in the process of being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program. For further information, visit the Company’s web site at www.xenoport.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…